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Human immunodeficiency virus (HIV) invades the central 
nervous system (CNS) soon after the initial systemic infection. 
Three pathways have been proposed whereby the virus 
breaches the blood-brain barrier and enters CNS parenchymal 
tissue: (i) HIV may be carried into the brain by infected 
macrophages-monocytes and/or CD4+ T lymphocytes (Trojan 
horse effect); (ii) cell-free virus may pass from the vascular 
compartment into brain tissue between cerebral microvascular 
endothelial cells (CMVECs) or by transmigration (transcytosis) 
through CMVECs; and (iii) following direct HIV infection of 
the specialised endothelial cells of the blood/brain barrier or 
CMVECs, newly formed HIV viral particles may be released 
into the cerebral compartment.1,2 Once established within the 
CNS compartment, the virus infects various cell populations, 
primarily perivascular macrophages and microglia, and 
activates several cell types including macrophages, microglia 
and astrocytes.2,3 The consequent inflammatory response 
induces neuronal apoptotic pathways causing neuronal death 
and attrition. Apoptosis may be activated by viral glycoproteins 
including gp120, tat, nef, vpr and gp41, or a variety of host-
derived mediators including inflammatory cytokines, free 
radicals and excitatory amino acids.4 There is some evidence 
suggesting that HIV may also inhibit neural progenitor cell 
proliferation, negatively affecting de novo neurogenesis.5
The consequence of the above is the development of 
neurological and neurocognitive manifestations.s Classically, 
HIV affects the immature brain causing static or progressive 
encephalopathy. Progressive encephalopathy has been 
defined by the Centers for Diseases Control (CDC), and is 
characterised by microcephaly, failure to attain or loss of 
neurodevelopmental milestones, or loss of intellectual ability, 
and acquired symmetrical motor defects.6 The prevalence 
of HIV encephalopathy varies from 13% to 35%, and up 
to 50% of children with full-blown AIDS (CDC clinical 
category C disease) have evidence of this complication.7 HIV 
encephalopathy may be the first AIDS-defining illness in as 
many as 18% of HIV-infected children.7 Encephalopathy may 
become static, plateau or progressively deteriorate.8 Without 
highly active antiretroviral therapy (HAART) the median 
survival of children who progress is less than 24 months.9
Aetiological agents other than HIV may cause neurological and/
or neurocognitive deficits in HIV-infected children. Because 
of generalised immunodeficiency, HIV-infected children are 
predisposed to CNS opportunistic infections including acute 
bacterial meningitis, tuberculous meningitis, cytomegalovirus 
co-infection, Epstein-Barr virus-associated primary lymphoma, 
and in older children cryptococcal meningitis.10-14 HIV-infected 
patients are at risk for thromboembolic strokes caused by 
disturbances in blood coagulation via antiphospholipid 
antibodies or reduced protein S concentration, and ischaemic 
strokes due to infections, coagulopathies or HIV-associated 
vasculopathy.15 Following initiation of antiretroviral therapy 
(HAART) an immune reconstitution inflammatory response 
to several CNS pathogens including John Cunningham 
(JC) virus, a polyomavirus, may occur resulting in CNS 
deterioration.16 Neurological manifestations may be complex 
in their presentation due to multiple pathologies.17 However, 
isolated neurocognitive deficits may occur, particularly in the 
presence of advanced HIV disease.18
Studies have reported on the frequency of CNS manifestations 
in HIV-infected children living in resource-constrained 
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Aim: To describe neurological and neurocognitive deficits in HIV-infected children and the short-term effect of highly active 
antiretroviral therapy (HAART) on the observed deficits 
Methods: In this prospective study, 39 children (15 females) were evaluated before the start of HAART and 30 reassessed 6 
months later. The subjects were evaluated with a range of cognitive tests used in everyday clinical practice. 
Results: At enrolment, the mean (±SD) age was 60±46 months, 17 (44%) and 22 (56%) had Centers for Disease Control (CDC) 
clinical category B and C disease respectively, and 36 (92%) had severe immunosuppression. At the start of HAART no child 
had cranial nerve or cerebellar dysfunction, but 13/29 (33.3%) had evidence of motor dysfunction. By 6 months 1 child had 
developed cerebellar dysfunction, but there was no statistically significant change in the frequency of motor dysfunction. 
Mean baseline performances on cognitive testing were generally subnormal. Between 33% and 81% of the children recorded 
subnormal intelligence quotients on various cognitive tests. Mean performances did not change significantly after 6 months 
of HAART.
Conclusion: Neurological and neurocognitive deficits are frequent in HIV-infected children. The prevalence and extent of 
deficits did not change significantly in response to short-term HAART, indicating neither spontaneous improvement nor 
deterioration during early treatment. 
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settings. These studies generally documented significantly 
higher prevalences of neurological and cognitive deficits in 
HIV-infected children compared with those who serorevert 
or in uninfected controls.19-22 An exception to this is described 
in a Ugandan study that showed similar frequencies of 
neurological and cognitive deficits in small groups of HIV-
infected, HIV-exposed but uninfected, and uninfected children 
of schoolgoing age.23 Neurological and cognitive deficits have 
been documented in up to 80% of HIV-infected children.22 The 
risk for neurodevelopmental delay may be greatest in those 
who have documented HIV infection at birth, compared with 
children who seroconvert after birth.21 In the present study 
we describe the neurological and neurocognitive deficits in a 
group of children with HIV infection in Cape Town, and assess 
the response of these deficits after 6 months on HAART. 
Methods
This prospective study was completed on the first group of 
HIV-infected children enrolled on the antiretroviral treatment 
programme at Red Cross Children’s Hospital, Cape Town, 
between February 2002 and December 2003. Children 
were started on HAART based on criteria derived from the 
Paediatric European Network for the Treatment of AIDS 
as previously described.24 The present study describes the 
neurological and neurocognitive effects in these children at 
two time points, before and after 6 months of HAART. This 
study overlapped with the establishment of a donor-funded 
antiretroviral treatment programme at the hospital during 
August 2002. The initial impact of this treatment programme 
was previously described.24,25 The Research Ethics Committee 
of the University of Cape Town approved the study (reference 
number 290/2002). Written informed consent was obtained 
from a parent or legal guardian prior to study entry.
Participants
A convenience sample of 40 ambulant children attending 
the outpatient HIV service were considered for inclusion. 
All children met criteria for starting HAART.24 All were 
commenced on a triple combination regimen comprising 
stavudine and lamivudine plus either ritonavir (18 children) 
or efavirenz (21 children). Children were excluded from the 
study if they had pre-existing neurocognitive disabilities due 
to causes other than HIV, previously documented neonatal 
hypoxic ischaemic encephalopathy, or were hospitalised at the 
time of neurocognitive testing. One child with a pre-existing 
genetic disorder was excluded. A further 2 children had 
possible non-HIV-related risk factors for neurodevelopmental 
delay; one child with premature birth, and the other with 
low Apgar scores and a history of prenatal alcohol exposure 
but no history of hypoxic ischaemic encephalopathy or 
features of fetal alcohol syndrome. Both these children were 
included. Thirty-nine children (15 females, 24 males) therefore 
participated in the study. 
Demographic and social data
At baseline, the mean age of the participants (± standard 
deviation, SD)was 60±46 months. The primary caregiver was 
the mother in 29 cases (74.4%) and another family member 
in 8 (20.5%), 1 child was in foster care, and 1 child had an 
unrelated legal guardian. Twenty-nine (74.4%) of caregivers 
were unemployed, 7 (17.4%) were employed, 2 (5.1%) were 
receiving a pension and one child was institutionalised in 
foster care. However, 62% (24) of the primary caregivers 
were receiving a social grant. At enrolment, 10 (25.6%) of 
the caregivers had achieved an education level ≥ grade 12, 
22 (56.4%) had completed grade 7 - 11, 5 (12.8%) had been 
educated to a level < grade 7, and the educational status of 2 
was unknown. Fourteen children (35.9%) were >6 years old 
and therefore eligible for school attendance. Of these 7 were 
attending school and had started at the appropriate age, 3 had 
never attended school because of financial reasons or poor 
health/recurrent infections, and 4 had either delayed school 
entry or failed a year. Whether or not the remaining 25 were 
attending preschool was not documented. The predominant 
languages spoken were Xhosa by 34 (87.2%) children, Xhosa 
at home and English at school by 2 (5.1%), Afrikaans by 1 
(2.6%), Zulu and Xhosa by 1 (2.6%), and Sotho and Xhosa by 
1 (2.6%). 
The severity of the children’s HIV infection was determined 
using the CDC clinical and immunological classification 
for children.6 Weight-for-age and height-for-age z-scores 
were calculated using EpiInfo 2000, version 1.0, Division of 
Surveillance and Epidemiology, CDC, Atlanta, Georgia. After 
baseline neurological and cognitive assessment, the children 
were commenced on standard three-drug triple combination 
antiretroviral therapy, comprising two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus either a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) or a protease inhibitor 
(PI). Response to HAART was determined by comparing 6-
month CD4 percentage, HIV-1 RNA concentration (viral 
load) and growth parameters with corresponding baseline 
measurements. Viral loads were expressed in log10 values.
Outcome measures
Neurological examination was completed at enrolment and 
after 6 months. This covered cranial nerves, cerebellar function 
and motor system, which included evaluation of reflexes, 
power, tone and gait. 
Cognitive testing was completed at baseline and after 6 
months using a battery of standardised tests covering the age 
range 0 - 13 years. Tests were administered according to their 
applicability to three age ranges; <4 years, 4 - 6 years and >6 
years (Table I). Four general tests of intelligence and one motor 
test were administered.
General tests of intelligence 
Griffiths Mental Development Scales26 measure progression 
of development in six areas: locomotor, personal-social, hearing 
and speech, eye and hand co-ordination, performance, and 
practical reasoning. The first five scales assess development 
from infancy to age 8 years, and the last scale from 3 years to 8 
years. Each subscale is expressed as a quotient of performance 
mental age as a percentage of chronological age. The general 
quotient (GQ) is a composite of all the subscales. Subscales 
can be used alone, with subscale means ranging from 99.79 
to 100.46 and standard deviations from 15.58 to 17.43. Norms 
for the Griffiths Scales are available for some South African 
population groups. The Griffiths Scales were administered to 
all children <6 years of age (N=26) (see Table I).
Test of the Reception of Grammar (TROG)27 consists of 
identification of 80 items depicting increasing complexity of 
syntactic and lexical grammar, and has been shown to be useful 
as a measure of verbal abilities in children with developmental 
disabilities. The TROG has been successfully used in studies 
on children with developmental disabilities in South Africa. 
The overall score may be expressed as a percentile. 
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Raven Progressive Coloured Matrices (Raven CPM)28 is a 
cross-cultural test that assesses non-verbal problem solving 
based on matching components of patterns. It is normed for 
children and has been used widely in cognitive research on 
developing countries. Test scores are reported as percentile 
scores. For interpretation, above the 95th centile is intellectually 
superior; above the 75th centile is above average; between 
the 25th and 75th centiles is intellectually average; below the 
25th centile is below average; and at or below the 5th centile 
represents intellectual impairment.
The Harris-Goodenough-Draw-A-Person Test (DAP),29 
adapted from the Goodenough Draw-a-Man Test originally 
developed as a scaled measure of non-verbal intelligence, 
was included in this study to represent a general screen for 
maturity of cognitive and non-verbal function in children. 
In this context, the test provides a useful tool with which to 
identify children who have cognitive, motor or visual-spatial 
delays in maturation. The Harris-Goodenough Draw-a-Person 
score was converted to a general intellectual function (IF) score 
by dividing the score obtained in months by the chronological 
age in months.24   
Motor test
Beery-Buktenica Developmental Test of Visual-Motor 
Integration30 is a pencil and paper test that measures the 
extent to which individuals can integrate their visual and 
motor abilities. This test, extensively used in clinical practice 
in South Africa, includes visual motor integration (VMI) as 
well as visual perception (VP) and motor co-ordination (MC) 
components. Scores were converted to percentiles using test 
manual norms.30 
All tests were performed in the patient’s first language, using 
an interpreter where appropriate. All test materials were 
available in Xhosa, Afrikaans and English, translated from the 
English originals.26-30 Standardised charts were used to convert 
TROG and Raven CPM percentiles into intelligence quotient 
(IQ) scores.27,28 An IQ, GQ or intellectual function (IF) score 
was considered sub-normal if <75.
During the study period, apart from HAART, the participants 
received no other specific interventions such as physical, 
occupational or speech therapy, because of lengthy waiting 
lists. 
Statistical analysis
The data were entered into a Microsoft Excel spreadsheet and 
analysed using standard statistical methods in SPSS Version 
10.0, SPSS Inc., Chicago, USA. The Lilliefors test for normality 
was applied to all sets of data. Baseline and 6-month results 
were analysed using the paired t-test for normally distributed 
data, or the Wilcoxon signed ranks sum test for non-normally 
distributed data. Pearson’s correlation coefficient was used 
to correlate neurocognitive results with either CD4% or log10 




Thirty (76.9%) children completed the 6-month assessment. 
The reasons for non-completion were: loss to follow-up (2), 
discontinuation of HAART because of poor adherence (2), 
died (3), and medically unfit or hospitalised at the time of the 
6-month evaluation (2). 
HIV status, nutrition and response to 
HAART
At the start of HAART 17 (44%) and 22 (56%) children had 
CDC clinical category B and C disease respectively. According 
to the CDC immunological classification, 3 (8%) were 
moderately immunosuppressed (immune category 2) and 36 
(92%) severely immunosuppressed (immune category 3). The 
initial CD4% (mean ± SD) was 9.3±4.7% and the initial log10 
viral load 5.59±0.75. Weight- and height-for-age z-scores were 
–2.52±1.29 and –3.05±1.28, respectively. At the start of HAART, 
27 (69.2%) and 29 (74.3%) were underweight and stunted, 
respectively. Twenty children (51.3%) were started on an 
NNTRI-based regimen and the remaining 19 children (48.7%) 
on a PI-based regimen. The change in CD4%, log10 viral load 
and nutritional status during the first 6 months of HAART in 
those children with paired samples was statistically significant 
and is described in Table II. After 6 months 16/22 (72.7%) 
achieved a viral load <400 copies/ml.
Neurological outcome
At the time of initial examiniation one child had a past history 
of seizures, i.e. had experienced a single generalised seizure 
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TAble I. COGNITIVe TeSTS AND AGeS Of 
ADMINISTRATION IN THe STuDy21-25 
Children 0 - 4 years old
•  Griffiths Scales of Mental Development
Children 4 - 6 years old
•   Griffiths Scales of Mental Development
•   Test for Reception of Grammar (TROG)
•   Raven Coloured Progressive Matrices (CPM)
•   Beery-Buktenica developmental tests for visual 
motor integration (VMI), visual perception (VP) and 
motor co-ordination (MC)
•   Harris-Goodenough Draw-A-Person Test (DAP)
Children >6 years old 
•  TROG
•  Ravens CPM
•  VMI/VP/MC 
•  Harris-Goodenough DAP
TAble II. CHANGe IN CD4 COuNT, HIV VIRAl 
lOAD AND NuTRITIONAl STATuS DuRING THe 





(mean ± SD) N p
CD4% 8.92±4.47 15.99±6.30 30 <0.0001
Log10 viral 
load








–2.96±1.22 –2.76±1.16 30 0.045
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related to fever. At the start of HAART no child had cranial 
nerve or cerebellar dysfunction. None of the children had 
neuroradiological investigations done before enrolment.  
Five weeks after commencing HAART one child 
developed cerebellar signs related to progressive 
multifocal leucoencephalopathy. Although he responded to 
glucocorticosteroids, he never fully recovered and residual 
cerebellar ataxia persisted.16 The findings on baseline and 6-
month motor system examinations are documented in Table 
III. All motor deficits documented on clinical examination 
were symmetrical, consistent with HIV encephalopathy. 
Neurocognitive assessment
A summary of GQs at baseline and 6 months for the Griffiths 
Mental Development Scales is set out in Table IV. Reasons 
for non-completion have been described. All baseline and 
post-HAART subscales were in the low normal, borderline 
normal or below normal range. Lower performance (in the 
mild disability range) was observed both at baseline and 
post HAART in locomotor, hearing and speech and motor 
performance subscale domains. There was no statistical 
difference in scores after 6 months of HAART. 
For children >4 years, the baseline and post-HAART test scores 
for TROG, Raven CPM, Beery-Buktenica VMI, VP, MC and 
Harris-Goodenough DAP are presented in Table V. As with 
the Griffiths Scales, all scores in this age group fell in the below 
average or below normal range, with specific deficits noted in 
language (TROG = 5th percentile) and visual perception (VP 
between 15th and 13th percentile) for age. The scores for tests 
administered remained similar at baseline and post-HAART; 
changes were not statistically significant.  
The percentages of children at baseline with IQ, GQ or IF 
scores below 75 are set out recorded in Table VI.
Correlations between neurocognitive measures and either 
CD4 percentage or viral load were not statistically significant.
Discussion
In this pilot study, a small number of HIV-infected children 
were screened for neurological and cognitive deficits. The 
neurocognitive tools used are employed in everyday paediatric 
neurodevelopmental practice in South Africa. They evaluated 
non-verbal (Griffiths scales of mental development, Ravens 
CPM and Harris-Goodenough DAP) and verbal (TROG) 
cognition, and visual perception (Beery-Buktenica tests). The 
tests were selected to cover the age range 0 - 13 years, i.e. the 
age range of HIV-infected children who attend the infectious 
diseases service at Red Cross Children’s Hospital. Furthermore, 
the assessment tools were translated into the three dominant 
languages of the Western Cape and administered in the first 
language of the participants. 
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TAble III. MOTOR SySTeM exAMINATION AT 








Normal motor  
examination
26 (66.7) 19 (63.3)
Hyperreflexia   9 (23.1)  9 (30)
Hyperreflexia and  
hypertonia
  1 (2.6)  1 (3.3)
Hyperreflexia and  
abnormal gait
  1 (2.6)  1 (3.3)
Hyperreflexia and 
clonus
  1 (2.6)  0
Hyperreflexia, hyper-
tonia and reduced power
  1 (2.6)  0
TAble IV. GRIffITHS MeNTAl DeVelOPMeNT 
SCAleS GeNeRAl quOTIeNTS AND  
Sub-quOTIeNTS AT bASelINe AND AfTeR 6 
MONTHS Of HAART
Griffiths Mental Develop-







General quotient (GQ) 71.6±16.3 72.7±14.8




Hearing & speech  
sub-quotient 
69.1±16.8 70.7±16.0
Eye & hand co-ordination 
sub-quotient
74.3±15.9 74.9±12.9
Performance sub-quotient 69±17.7 69.8±18.8
Practical reasoning  
sub-quotient 
70.8±16.5 71.5±16.2
TAble V. COGNITIVe TeST SCOReS IN  
CHIlDReN >4 yeARS OlD AT bASelINe AND 
AfTeR 6 MONTHS Of HAART
baseline 6 months
Test Mean ± SD N Mean ± SD N
TROG percentile   5.2±8.5 16   5.4±8.2 16
Ravens CMP 
percentile 
20.8±20.1 17 22.5±22.3 16
VMI percentile   9.9± 1.3 18 11.59±11.5 17
VP percentile 15.3±12.7 18  13.6±24 17
MC percentile 23.9±17.6 18 17.61±16.5 17
DAP intellectual 
function score
79.2±17.9 18  83.8±19.2 17
TAble VI. PeRCeNTAGeS Of CHIlDReN AT 
bASelINe wITH Sub-NORMAl INTellIGeNCe 
quOTIeNT (Iq), GeNeRAl quOTIeNT (Gq) OR 





Griffiths (GQ)            26         62% (16)
TROG (IQ)             16          81% (13)
Ravens CMP (IQ)            17         59% (10)
Harris-Good-
enough DAP (IF)
           18         33% (6)
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Notwithstanding the study limitations 
discussed below, our findings in a South 
African population are consistent with 
other studies in developing countries 
which describe a significant rate of early 
neurocognitive and motor developmental 
disabilities in HIV-infected children.19-22 
Experience from these settings suggests 
that HIV is a major determinant of 
neurocognitive dysfunction.19-22 Notably, 
in this study language deficits in all age 
groups were greatest, as evidenced by 
the Griffiths Mental Development Scales 
and TROG scores, which were in the mild 
disability range. This could be anticipated, 
as language is the most representative 
developmental domain of higher order 
cognitive function and would therefore be 
expected to be the most sensitive to, and 
affected by, the CNS challenges described 
in HIV infection. 
The study had several limitations. Despite careful selection of 
children and the exclusion of those with pre-existing deficits 
due to causes other than HIV, the socio-demographic and 
nutritional profile of the participants suggests that factors such 
as limited maternal education, poor household intellectual 
stimulation and malnutrition may themselves have impacted 
negatively on neurocognitive development. Furthermore, 
maternal emotional status, which could have influenced 
development, was not evaulated. While the spectrum of motor 
defects documented in the patient group is consistent with 
HIV encephalopathy, the absence of an HIV-uninfected control 
group for comparison limits our ability to estimate the relative 
contribution of HIV to neurocognitive dysfunction. However, 
a crude comparison of neurocognitive scores of HIV-infected 
children in the present study and scores of uninfected children 
from low socio-economic communities in the Western Cape 
who were enrolled in other studies showed that verbal and 
non-verbal intelligence performances of HIV-infected children 
were lower, and comparable to performance levels of children 
with mild developmental disability.31,32
The small, non-random sample in this study limits our 
ability to generalise our findings of prevalence and range of 
neurological and cognitive deficits to other groups of HIV-
infected children in South Africa. Despite these weaknesses, 
the research findings strengthen the hypothesis that HIV-
infected children in South Africa are vulnerable to neurological 
and cognitive problems and that they should be identified and 
actively managed. 
Antiretroviral therapy may prevent CNS manifestations 
of HIV infection and reverse the process in children with 
established HIV encephalopathy (although not completely, as 
there are residual features of arrested HIV encephalopathy).33,34 
The age of starting HAART is an important determinant of 
neurological and neurocognitive outcome. When HAART is 
commenced in HIV-infected children during early infancy, the 
prevalence of CNS effects may be reduced to less than 2%.33 
In the present study, the neurological and cognitive deficits 
observed in the children remained static after 6 months of 
HAART, i.e. there was neither spontaneous resolution nor 
deterioration of the children’s function. Non-reversal after 
only 6 months of HAART was not completely unanticipated. 
Although HAART causes decline in cerebrospinal fluid HIV 
viral load, reversal of neurological and cognitive deficits caused 
by HIV is unpredictable and arrested 
encephalopathy with persistent deficits 
are frequent.34 Because encephalopathy 
was not classified at baseline we were 
unable to determine whether some 
children with the progressive type were 
beginning to develop arrested HIV 
encephalopathy after 6 months of HAART. 
Furthermore, the children were exposed 
to unchanged socio-demographic factors 
throughout the study period, which may 
have contributed to non-improvement of 
CNS deficits. Documentation of outcomes 
over a longer time period would better 
elucidate neurodevelopmental trajectory 
and response to HAART and in this study 
group could be achieved by longitudinal 
follow-up, specifically to the age of regular 
school attendance. One factor that may 
affect the long-term clinical response to 
HAART is the variable penetration of the 
CNS compartment by antiretroviral agents, which should be 
evaluated in studies of longer duration. 
In South Africa, there is currently limited potential to alter 
poverty-related parameters that impact on the intellectual 
development of children. However, increased intellectual 
stimulation is possible in resource-limited settings including 
South Africa through optimal utilisation of existing resources, 
such as early child-care facilities and toy libraries. These 
potential interventions should be explored in the context of 
paediatric HIV infection.  
In conclusion, because of delayed introduction of HAART and 
a continued low coverage rate among HIV-infected children in 
South Africa, neurological and cognitive deficits are likely to 
be highly prevalent. Early, persisting receptive and expressive 
language delay in children is a well-documented predictor of 
poor long-term educational and life achievement outcomes. 
This has significant implications for children with HIV infection, 
their families, communities and society in general. A shift in 
national treatment guidelines towards earlier introduction of 
HAART, and a commitment to early intervention with child 
development programmes, should lead to reduced prevalence 
of CNS deficits and improved neurocognitive outcomes.
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